|
1）アミロイドーシスに関する調査研究班．アミロイドーシス診療ガイドライン2010. http: //amyloid1. umin. ne. jp/guideline2010. pdf p. p. 27-35
|
|
|
|
|
2）西 慎一，乳原善文．透析アミロイドーシス．In: 山田正仁, 編．アミロイドーシス診療のすべて―ガイドライン完全解説. 東京：医歯薬出版；2011. p. 87-101
|
|
|
|
|
|
3）Liu C, Sawaya MR, Eisenberg D. β2-microglobulin forms three-dimensional domain-swapped amyloid fibrils with disulfide linkages. Nat Struct Mol Biol. 2011; 18(1): 49-55
|
|
|
|
|
4）Yamamoto S, Kazama JJ, Narita I, et al. Recent progress in understanding dialysis-related amyloidosis. Bone. 2009; 45 (Suppl 1): S39-42
|
|
|
|
|
|
5）Yanagi K, Sakurai K, Yoshimura Y, et al. The monomer-seed interaction mechanism in the formation of the β2-microglobulin amyloid fibril clarified by solution NMR techniques. J Mol Biol. 2012. Jun 6 [Epub ahead of print]
|
|
|
|
|
|
6）日本透析医学会．慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌. 2012; 45(4): 301-56
|
|
|
|
|
|
7）Porter MY, Routledge KE, Radford SE, et al. Characterization of the response of primary cells relevant to dialysis-related amyloidosis to β2-microglobulin monomer and fibrils. PLoS One. 2011; 6(11): e27353
|
|
|
|
|
|
8）Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985; 129(3): 701-6
|
|
|
|
|
|
9）日本透析医学会統計調査委員会, 編. 我が国の慢性透析療法の現況. 日本透析医学会．2000. p. 869-71
|
|
|
|
|
|
10）Yamamoto S, Kazama JJ, Maruyama H, et al. Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders. Clin Nephrol. 2008; 70(6): 496-502
|
|
|
|
|
|
11）Kopec J, Gadek A, Drozdz M, et al. Carpal tunnel syndrome in hemodialysis patients as a dialysis-related amyloidosis manifestation-incidence, risk factors and results of surgical treatment. Med Sci Monit. 2011; 17(9): CR505-9
|
|
|
|
|
|
12）Kuchle C, Fricke H, Held E, et al. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol. 1996; 16(6): 484-8
|
|
|
|
|
|
13）Locatelli F, Hannedouche T, Jacobson S, et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol. 1999; 12(2): 85 -8
|
|
|
|
|
|
14）Baz M, Durand C, Ragon A, et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs. 1991; 14(11): 681-5
|
|
|
|
|
|
15）Locatelli F, Marcelli D, Conte F, et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int. 1999; 55(1): 286-93
|
|
|
|
|
|
16）Bardin T, Lebail-Darne JL, Zingraff J, et al. Dialysis arthropathy: outcome after renal transplantation. Am J Med. 1995; 99(3): 243-8
|
|
|
|
|
|
17）Mourad G, Argiles A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol. 1996; 7(5): 798-804
|
|
|
|
|
|
18）Gejyo F, Kawaguchi Y, Hara S, et al. Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs. 2004; 28(4): 371-80
|
|
|
|
|
|
19）Yamamoto Y, Hirawa N, Yamaguchi S, et al. Long-term efficacy and safety of the small-sized β2-microglobulin adsorption column for dialysis-related amyloidosis. Ther Apher Dial. 2011; 15(5): 466-74
|
|
|
|
|
20）Kuragano T, Inoue T, Yoh K, et al. Effectiveness of β(2)-microglobulin adsorption column in treating dialysis-related amyloidosis: a multicenter study. Blood Purif. 2011; 32(4): 317-22
|
|
|
|
|
|
21）Yang TH, Lin BJ, Ma YL, et al. In vitro removal of beta-2-microglobulin from uremic blood with an immunoadsorption wall. Artif Organs. 2012; 36(1): 78-86
|
|
|
|
|
|
22）Stamopoulos D, Bouziotis P, Benaki D, et al. Nanobiotechnology for the prevention of dialysis-related amyloidosis. Ther Apher Dial. 2009; 13(1): 34-41
|
|
|
|
|
|
23）Capitanini A, Galligani C, Lange S, et al. Upper limb disability in hemodialysis patients: evaluation of contributing factors aside from amyloidosis. Ther Apher Dial. 2012; 16(3): 242-7
|
|
|
|
|
|
24）Kutsuna T, Matsunaga A, Takagi Y, et al. Development of a novel questionnaire evaluating disability in activities of daily living in the upper extremities of patients undergoing maintenance hemodialysis. Ther Apher Dial. 2011; 15(2): 185-94
|
|
|
|
|
|
25）Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int. 2008; 28(11): 1155-9
|
|
|
|
|
|
26）Ueno T, Takeda K, Nagata M. Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant. 2012; 27(2): 633-9
|
|
|
|
|